Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Receivables (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Receivables readings, the most recent being $353762.5 for Q4 2022.

  • On a quarterly basis, Receivables rose 9.53% to $353762.5 in Q4 2022 year-over-year; TTM through Dec 2022 was $353762.5, a 9.53% increase, with the full-year FY2022 number at $353762.5, up 9.53% from a year prior.
  • Receivables hit $353762.5 in Q4 2022 for Cardiol Therapeutics, up from -$34463.7 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $353762.5 in Q4 2022 to a low of -$377688.9 in Q2 2021.
  • Median Receivables over the past 3 years was -$34463.7 (2022), compared with a mean of $18464.0.
  • The widest YoY moves for Receivables: up 100.73% in 2022, down 9.53% in 2022.
  • Cardiol Therapeutics' Receivables stood at $168693.0 in 2020, then surged by 91.47% to $322988.5 in 2021, then grew by 9.53% to $353762.5 in 2022.
  • The last three reported values for Receivables were $353762.5 (Q4 2022), -$34463.7 (Q3 2022), and $2748.3 (Q2 2022) per Business Quant data.